vs

Side-by-side financial comparison of STANDARD BIOTOOLS INC. (LAB) and OP Bancorp (OPBK). Click either name above to swap in a different company.

OP Bancorp is the larger business by last-quarter revenue ($24.3M vs $19.6M, roughly 1.2× STANDARD BIOTOOLS INC.). On growth, OP Bancorp posted the faster year-over-year revenue change (13.7% vs -11.5%). OP Bancorp produced more free cash flow last quarter ($23.4M vs $-23.1M). Over the past eight quarters, OP Bancorp's revenue compounded faster (11.4% CAGR vs -12.2%).

Standard BioTools Inc., previously known as Fluidigm Corp., is an American life science tools company that offers analytical mass cytometry systems for flow cytometry and tissue imaging, along with associated assays and reagents, as well as an automated genomic analysis instrument and a variety of microfluidic arrays, or integrated fluidic circuits (IFCs), and consumables with fully kitted reagents. Custom assays and services are available with all systems and applications.

OP Bancorp is the bank holding company for Open Bank, a community-oriented commercial bank headquartered in California, United States. It provides a full range of banking solutions including deposit accounts, commercial real estate loans, small business financing, and consumer lending products, primarily catering to small and medium-sized enterprises, local immigrant communities, and retail clients across Southern California.

LAB vs OPBK — Head-to-Head

Bigger by revenue
OPBK
OPBK
1.2× larger
OPBK
$24.3M
$19.6M
LAB
Growing faster (revenue YoY)
OPBK
OPBK
+25.2% gap
OPBK
13.7%
-11.5%
LAB
More free cash flow
OPBK
OPBK
$46.4M more FCF
OPBK
$23.4M
$-23.1M
LAB
Faster 2-yr revenue CAGR
OPBK
OPBK
Annualised
OPBK
11.4%
-12.2%
LAB

Income Statement — Q3 FY2025 vs Q4 FY2025

Metric
LAB
LAB
OPBK
OPBK
Revenue
$19.6M
$24.3M
Net Profit
$-34.7M
Gross Margin
48.5%
Operating Margin
-168.5%
39.2%
Net Margin
-177.4%
Revenue YoY
-11.5%
13.7%
Net Profit YoY
-28.8%
EPS (diluted)
$-0.09
$0.48

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
LAB
LAB
OPBK
OPBK
Q4 25
$24.3M
Q3 25
$19.6M
$24.5M
Q2 25
$21.8M
$23.7M
Q1 25
$40.8M
$22.2M
Q4 24
$21.3M
Q3 24
$22.1M
$20.7M
Q2 24
$22.5M
$20.4M
Q1 24
$45.5M
$19.6M
Net Profit
LAB
LAB
OPBK
OPBK
Q4 25
Q3 25
$-34.7M
$6.7M
Q2 25
$-33.5M
$6.3M
Q1 25
$-26.0M
$5.6M
Q4 24
Q3 24
$-26.9M
$5.4M
Q2 24
$-45.7M
$5.4M
Q1 24
$-32.2M
$5.2M
Gross Margin
LAB
LAB
OPBK
OPBK
Q4 25
Q3 25
48.5%
Q2 25
48.8%
Q1 25
48.4%
Q4 24
Q3 24
54.9%
Q2 24
46.1%
Q1 24
53.1%
Operating Margin
LAB
LAB
OPBK
OPBK
Q4 25
39.2%
Q3 25
-168.5%
39.5%
Q2 25
-118.1%
35.7%
Q1 25
-80.8%
34.6%
Q4 24
31.2%
Q3 24
-120.9%
36.5%
Q2 24
-134.5%
37.2%
Q1 24
-132.2%
37.1%
Net Margin
LAB
LAB
OPBK
OPBK
Q4 25
Q3 25
-177.4%
27.4%
Q2 25
-153.7%
26.7%
Q1 25
-63.8%
25.0%
Q4 24
Q3 24
-122.0%
26.2%
Q2 24
-203.3%
26.7%
Q1 24
-70.6%
26.7%
EPS (diluted)
LAB
LAB
OPBK
OPBK
Q4 25
$0.48
Q3 25
$-0.09
$0.45
Q2 25
$-0.09
$0.42
Q1 25
$-0.07
$0.37
Q4 24
$0.33
Q3 24
$-0.07
$0.36
Q2 24
$-0.12
$0.36
Q1 24
$-0.27
$0.34

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
LAB
LAB
OPBK
OPBK
Cash + ST InvestmentsLiquidity on hand
$129.4M
$167.3M
Total DebtLower is stronger
Stockholders' EquityBook value
$399.7M
$227.9M
Total Assets
$539.6M
$2.7B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
LAB
LAB
OPBK
OPBK
Q4 25
$167.3M
Q3 25
$129.4M
$166.7M
Q2 25
$158.6M
$205.4M
Q1 25
$150.9M
$198.9M
Q4 24
$134.9M
Q3 24
$210.6M
$166.8M
Q2 24
$269.8M
$127.7M
Q1 24
$287.1M
$139.2M
Total Debt
LAB
LAB
OPBK
OPBK
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
$55.2M
Q2 24
$55.1M
Q1 24
$55.0M
Stockholders' Equity
LAB
LAB
OPBK
OPBK
Q4 25
$227.9M
Q3 25
$399.7M
$221.5M
Q2 25
$424.5M
$213.7M
Q1 25
$454.6M
$210.1M
Q4 24
$205.0M
Q3 24
$489.3M
$203.6M
Q2 24
$510.3M
$195.9M
Q1 24
$577.3M
$194.7M
Total Assets
LAB
LAB
OPBK
OPBK
Q4 25
$2.7B
Q3 25
$539.6M
$2.6B
Q2 25
$557.0M
$2.6B
Q1 25
$579.6M
$2.5B
Q4 24
$2.4B
Q3 24
$681.5M
$2.4B
Q2 24
$708.7M
$2.3B
Q1 24
$777.7M
$2.2B
Debt / Equity
LAB
LAB
OPBK
OPBK
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
0.11×
Q2 24
0.11×
Q1 24
0.10×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
LAB
LAB
OPBK
OPBK
Operating Cash FlowLast quarter
$-22.2M
$26.2M
Free Cash FlowOCF − Capex
$-23.1M
$23.4M
FCF MarginFCF / Revenue
-118.1%
96.2%
Capex IntensityCapex / Revenue
4.5%
11.5%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-111.1M
$43.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
LAB
LAB
OPBK
OPBK
Q4 25
$26.2M
Q3 25
$-22.2M
$23.9M
Q2 25
$-20.7M
$-7.0M
Q1 25
$-30.3M
$5.6M
Q4 24
$31.2M
Q3 24
$-27.9M
$13.3M
Q2 24
$-39.0M
$15.8M
Q1 24
$-62.5M
$-3.2M
Free Cash Flow
LAB
LAB
OPBK
OPBK
Q4 25
$23.4M
Q3 25
$-23.1M
$23.4M
Q2 25
$-22.6M
$-7.7M
Q1 25
$-35.3M
$4.2M
Q4 24
$29.7M
Q3 24
$-30.1M
$12.8M
Q2 24
$-41.0M
$15.7M
Q1 24
$-63.3M
$-3.2M
FCF Margin
LAB
LAB
OPBK
OPBK
Q4 25
96.2%
Q3 25
-118.1%
95.6%
Q2 25
-103.6%
-32.5%
Q1 25
-86.6%
19.0%
Q4 24
139.0%
Q3 24
-136.4%
61.5%
Q2 24
-182.2%
77.0%
Q1 24
-138.9%
-16.6%
Capex Intensity
LAB
LAB
OPBK
OPBK
Q4 25
11.5%
Q3 25
4.5%
2.3%
Q2 25
8.7%
3.0%
Q1 25
12.4%
6.4%
Q4 24
7.3%
Q3 24
10.2%
2.8%
Q2 24
8.6%
0.4%
Q1 24
1.7%
0.5%
Cash Conversion
LAB
LAB
OPBK
OPBK
Q4 25
Q3 25
3.57×
Q2 25
-1.10×
Q1 25
1.02×
Q4 24
Q3 24
2.45×
Q2 24
2.90×
Q1 24
-0.60×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

LAB
LAB

Consumables$8.7M45%
Services And Other Revenue$5.8M29%
Instruments$5.1M26%

OPBK
OPBK

Segment breakdown not available.

Related Comparisons